Items Tagged ‘colorectal cancer’

July 28th, 2016

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers

By

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These results were recently published in the Journal of the National Cancer Institute. Among patients with colorectal cancer that has spread to […]

View full entry

Tags: 5fu, Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, crc, dmmr, eloxatin, mismatch repair, News, oxaliplatin, Rectal Cancer, Stages I-III Rectal Cancer


May 11th, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

By

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, herceptin, lapatinib, News, Rectal Cancer, trastuzumab, Tykerb


May 2nd, 2016

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection

By

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing colorectal cancer who choose not to undergo other colorectal cancer screening methods specified in […]

View full entry

Tags: approval, Colon Cancer, colorectal cancer, EPI proColon, fda, News, non-invasive, Rectal Cancer, risk, screening, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


January 28th, 2016

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing

By

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, KRAS exon 2, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, Stages I-III Rectal Cancer, vectibix


September 30th, 2015

Lonsurf® Approved for the Treatment of Colorectal Cancer

By

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although death rates from colorectal cancer have declined in the past 10 years which is thought to be due […]

View full entry

Tags: advanced, Colon Cancer, colorectal cancer, fda, Lonsurf, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, tipiracil, trifluridine


August 11th, 2015

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy

By

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers have announced that that drug has extended overall survival, the primary goal of the study. Vectibix is a targeted therapy that […]

View full entry

Tags: Colon Cancer, colorectal cancer, kras, metastatic colorectal cancer, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, vectibix, wild-type


July 21st, 2015

Cancers Caught During Screening Colonoscopy are More Survivable

By

Patients whose colorectal cancer (CRC) is detected during a screening colonoscopy are likely to survive longer than those who wait until they have symptoms before having the test, according to a study in the July issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE). The study, […]

View full entry

Tags: Colon Cancer, colonoscopy, colorectal cancer, News, Rectal Cancer, screening, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


June 23rd, 2015

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

By

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal […]

View full entry

Tags: Colon Cancer, colorectal cancer, irinotecan, metastatic, News, oxaliplatin, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


March 23rd, 2015

Treatment Outcomes in Stage III Colon Cancer Appear Better in Aspirin, COX-2 Inhibitor Users

By

According to the results of a study recently reported in the Journal of the National Cancer Institute, patients with stage III colon cancer who take aspirin or other agents that inhibit cyclooxygenase-2 near the time of adjuvant chemotherapy appear to have a lower risk of cancer recurrence. It has long been suggested that aspirin and […]

View full entry

Tags: aspirin, celecoxib, Colon Cancer, colorectal cancer, COX-2, cyclooxygenase-2 inhibitors, News, Stage III colon cancer


March 17th, 2015

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer

By

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal cancer Immunotherapy Treatment Evaluation (“XCITE”), assesses XBiotech’s True Human™ monoclonal antibody (XilonixTM) for the treatment of […]

View full entry

Tags: Colon Cancer, colorectal cancer, immunotherapy, metastatic colorectal cance, monoclonal antibody, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xbiotech, xcite


February 19th, 2015

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer

By

The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium, January 15–17, in San Francisco, California.[1] According to estimates from the American Cancer Society, 93,090 cases of colon cancer and 39,610 cases of rectal cancer will be diagnosed in 2015. Colorectal […]

View full entry

Tags: advanced colorectal cancer, clinical trial, Colon Cancer, colon cancer treatment, colorectal cancer, crc, interleukin, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


January 16th, 2015

Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer

By

The results of an international phase III study evaluating 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy will be presented at the upcoming Gastrointestinal Symposium in San Francisco. The trial results suggest that a combination of the targeted drug Cyramza™ (ramucirumab) and FOLFIRI chemotherapy provides a survival advantage over […]

View full entry

Tags: Colon Cancer, colorectal cancer, cyramza, folfiri, News, ramucirumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


January 15th, 2015

Aggressive Chemotherapy Doubles Survival of Patients with Metastatic Colon Cancer

By

According to the results of a clinical trial presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, treatment of patients with metastatic colorectal cancer with a four-drug chemotherapy regimen plus Avastin® (bevacizumab) doubles survival when compared to a standard three drug regimen and Avastin. According to estimates from the American Cancer Society, more than […]

View full entry

Tags: avastin, bevacizumab, Colon Cancer, colorectal cancer, crc, folfiri, FOLFOX, News, Stage IV (D)/Relapsed Colon Cancer


November 3rd, 2014

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer

By

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival in adults with inoperable metastatic colorectal cancer. According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about 40,000 new cases […]

View full entry

Tags: Colon Cancer, colorectal cancer, folfiri, folfoxiri, metastatic, metastatic colorectal cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


October 23rd, 2014

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about 40,000 new cases of rectal cancer were diagnosed in […]

View full entry

Tags: Colon Cancer, colorectal cancer, News, Rectal Cancer, refractory colorectal cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, TAS-102